Epilepsy-associated neurocognitive disorders (EAND) in an onchocerciasis-endemic rural community in Cameroon: A population-based case-control study.


Journal

Epilepsy & behavior : E&B
ISSN: 1525-5069
Titre abrégé: Epilepsy Behav
Pays: United States
ID NLM: 100892858

Informations de publication

Date de publication:
11 2020
Historique:
received: 24 03 2020
revised: 16 08 2020
accepted: 16 08 2020
pubmed: 14 9 2020
medline: 15 4 2021
entrez: 13 9 2020
Statut: ppublish

Résumé

Epilepsy affects at least 50 million individuals worldwide, especially in sub-Saharan Africa (sSA). Cognitive impairment is common in people with epilepsy (PWE) yet, little is known on the burden of cognitive impairment in people with epilepsy in sSA. This study was thus designed to assess cognitive impairment in PWE or epilepsy-associated neurocognitive disorders (EAND) in a rural population in Cameroon. This was a case-control study including PWE and age/sex-matched healthy controls from July to September 2017 in Bilomo, a village in the Mbam and Kim Division. The Montreal Cognitive Assessment (MoCA), International HIV Dementia Scale (IHDS), Dubois' Five Word testing, Frontal Assessment Battery (FAB), Isaac's Set Test and the Clock drawing test were administered to the study participants to evaluate global and specific cognitive functions. Eighty participants were included (40 cases and 40 controls) with a mean age of 25.78 years. Using the MoCA, 87.5% of cases had cognitive impairment, against 37.5% of controls (p < 0.001; OR 11.67; CI 3.40-45.09). Using the IHDS, the prevalence of global cognitive impairment was 84.6% among the cases against 40% for the controls (p = <0.001; OR 7.07; CI 2.29-29.19). Specifically, executive function deficits (92.5% of cases vs 40.0% of controls p = <0.001 OR = 18.50 CI; 4.48-105.08) and decreased verbal fluency (100% of cases against 45% of controls p < 0.001) were the most affected cognitive domains. Longer duration of epilepsy and higher seizure frequency were associated with global cognitive impairment. Low level of education was associated with both decreased verbal fluency and executive dysfunction while a longer stay in Bilomo correlated with poor results on the Isaac's Set Test. The prevalence of cognitive impairment appears to be much higher in PWE in the Mbam valley, particularly decreased executive function and verbal fluency, than in people without epilepsy. Longer disease duration, higher seizure frequency, low level of education and length of stay in Bilomo are associated with poorer cognitive performance. More studies are needed to refine evaluation tools to better characterize and manage EAND in sSA.

Sections du résumé

BACKGROUND
Epilepsy affects at least 50 million individuals worldwide, especially in sub-Saharan Africa (sSA). Cognitive impairment is common in people with epilepsy (PWE) yet, little is known on the burden of cognitive impairment in people with epilepsy in sSA. This study was thus designed to assess cognitive impairment in PWE or epilepsy-associated neurocognitive disorders (EAND) in a rural population in Cameroon.
METHODS
This was a case-control study including PWE and age/sex-matched healthy controls from July to September 2017 in Bilomo, a village in the Mbam and Kim Division. The Montreal Cognitive Assessment (MoCA), International HIV Dementia Scale (IHDS), Dubois' Five Word testing, Frontal Assessment Battery (FAB), Isaac's Set Test and the Clock drawing test were administered to the study participants to evaluate global and specific cognitive functions.
RESULTS
Eighty participants were included (40 cases and 40 controls) with a mean age of 25.78 years. Using the MoCA, 87.5% of cases had cognitive impairment, against 37.5% of controls (p < 0.001; OR 11.67; CI 3.40-45.09). Using the IHDS, the prevalence of global cognitive impairment was 84.6% among the cases against 40% for the controls (p = <0.001; OR 7.07; CI 2.29-29.19). Specifically, executive function deficits (92.5% of cases vs 40.0% of controls p = <0.001 OR = 18.50 CI; 4.48-105.08) and decreased verbal fluency (100% of cases against 45% of controls p < 0.001) were the most affected cognitive domains. Longer duration of epilepsy and higher seizure frequency were associated with global cognitive impairment. Low level of education was associated with both decreased verbal fluency and executive dysfunction while a longer stay in Bilomo correlated with poor results on the Isaac's Set Test.
CONCLUSION
The prevalence of cognitive impairment appears to be much higher in PWE in the Mbam valley, particularly decreased executive function and verbal fluency, than in people without epilepsy. Longer disease duration, higher seizure frequency, low level of education and length of stay in Bilomo are associated with poorer cognitive performance. More studies are needed to refine evaluation tools to better characterize and manage EAND in sSA.

Identifiants

pubmed: 32920377
pii: S1525-5050(20)30617-X
doi: 10.1016/j.yebeh.2020.107437
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107437

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Alfred K Njamnshi (AK)

Department of Neurology, Central Hospital Yaoundé, Yaoundé, Cameroon; Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon & Geneva, Switzerland; Faculty of Medicine & Biomedical Sciences, The University of Yaoundé I, Yaoundé, Cameroon. Electronic address: alfred.njamnshi@brainafrica.org.

Eric-Samuel Chokote (ES)

Department of Neurology, Central Hospital Yaoundé, Yaoundé, Cameroon; Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon & Geneva, Switzerland; Faculty of Medicine & Biomedical Sciences, The University of Yaoundé I, Yaoundé, Cameroon.

Leonard Ngarka (L)

Department of Neurology, Central Hospital Yaoundé, Yaoundé, Cameroon; Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon & Geneva, Switzerland; Faculty of Medicine & Biomedical Sciences, The University of Yaoundé I, Yaoundé, Cameroon.

Leonard N Nfor (LN)

Department of Neurology, Central Hospital Yaoundé, Yaoundé, Cameroon; Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon & Geneva, Switzerland; Faculty of Medicine & Biomedical Sciences, The University of Yaoundé I, Yaoundé, Cameroon.

Earnest N Tabah (EN)

Department of Neurology, Central Hospital Yaoundé, Yaoundé, Cameroon; Faculty of Medicine & Biomedical Sciences, The University of Yaoundé I, Yaoundé, Cameroon; Ministry of Public Health, Yaoundé, Cameroon.

Jonas G Basseguin Atchou (JGB)

Department of Neurology, Central Hospital Yaoundé, Yaoundé, Cameroon; Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon & Geneva, Switzerland; Faculty of Medicine & Biomedical Sciences, The University of Yaoundé I, Yaoundé, Cameroon.

Samuel A Angwafor (SA)

Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon & Geneva, Switzerland; Department of Neurology, University College London, London, United Kingdom; Faculty of Health Sciences, University of Bamenda, Bamenda, Cameroon.

Cyrille Nkouonlack (C)

Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon & Geneva, Switzerland; Department of Neurology, Regional Hospital Buea, Buea, Cameroon; Department of Clinical Sciences, Faculty of Health Sciences, University of Buea, Buea, Cameroon.

Michel K Mengnjo (MK)

Department of Neurology, Central Hospital Yaoundé, Yaoundé, Cameroon; Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon & Geneva, Switzerland; Faculty of Medicine & Biomedical Sciences, The University of Yaoundé I, Yaoundé, Cameroon.

Wepnyu Y Njamnshi (WY)

Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon & Geneva, Switzerland; Faculty of Medicine & Biomedical Sciences, The University of Yaoundé I, Yaoundé, Cameroon; Department of Neurology and Neuropsychology, University of Fribourg, Fribourg, Switzerland.

Fidèle Dema (F)

Department of Neurology, Central Hospital Yaoundé, Yaoundé, Cameroon; Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon & Geneva, Switzerland; Ministry of Public Health, Yaoundé, Cameroon.

Godwin Y Tatah (GY)

Department of Neurology, Central Hospital Yaoundé, Yaoundé, Cameroon; Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon & Geneva, Switzerland; Neurology Department, CH Saint-Nazaire, Saint-Nazaire, France.

Anne-Cecile Zoung-KanyiBissek (AC)

Faculty of Medicine & Biomedical Sciences, The University of Yaoundé I, Yaoundé, Cameroon; Department of Health Operations Research, Ministry of Public Health, Yaoundé, Cameroon.

Jean-Marie Annoni (JM)

Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon & Geneva, Switzerland; Department of Neurology and Neuropsychology, University of Fribourg, Fribourg, Switzerland.

Nicolas Ruffieux (N)

Department of Special Education, University of Fribourg, Fribourg, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH